Aurobindo obtains FDA OK for generic Daliresp
Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with associated with chronic bronchitis.
The Food and Drug Administration has given Aurobindo the green light for roflumilast tablets, 500 mcg.
The medication is the generic of AstraZeneca’s Daliresp.
[Read more: Aurobindo receives FDA approval for 3 generics]
Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Roflumilast tablets have a market value of roughly $170.3 million for the 12 ending April 2023, per IQVIA April 2023 data.
[Read more: Aurobindo obtains FDA OK for 2 generics]